This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Cumberland Pharmaceuticals has agreed to sell its branded commercial drug portfolio to Canada-based Apotex for $100m in cash.

The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.

Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Tavapadon will enter a competitive but commercially attractive market after a likely regulatory submission following post-hoc data.

Results provide evidence needed to challenge the step-through reimbursement requirements that have restricted Qulipta's uptake in Europe.

OZMOSI and Planview have partnered to link external scientific data with internal R&D planning to support pharmaceutical organisations.

In April 2026, Biogen announced that it would acquire exclusive rights to TJ Biopharma’s felzartamab in Greater China for up to $850m.

This Durham-based facility will be AbbVie’s first manufacturing site in the state, and will become a centre of excellence for SVP production.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.

UK Biobank data from all 500,000 participants within the charity’s health database was put up for sale on the Chinese e-commerce website Alibaba.